The stock of Allogene Therapeutics Inc (ALLO) has seen a 11.94% increase in the past week, with a 11.11% gain in the past month, and a 17.65% flourish in the past quarter. The volatility ratio for the week is 11.70%, and the volatility levels for the past 30 days are at 7.46% for ALLO. The simple moving average for the last 20 days is 10.87% for ALLO stock, with a simple moving average of -5.74% for the last 200 days.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALLO is 138.20M, and currently, short sellers hold a 28.45% ratio of that floaft. The average trading volume of ALLO on November 05, 2024 was 1.90M shares.
ALLO) stock’s latest price update
Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a rise in its stock price by 10.29 in relation to its previous close of 2.72. However, the company has experienced a 11.94% gain in its stock price over the last five trading sessions. zacks.com reported 2024-10-31 that Allogene Therapeutics (ALLO) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at 11.10% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.05% of loss for the given period.
Volatility was left at 7.46%, however, over the last 30 days, the volatility rate increased by 11.70%, as shares surge +16.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.94% upper at present.
During the last 5 trading sessions, ALLO rose by +11.94%, which changed the moving average for the period of 200-days by -2.91% in comparison to the 20-day moving average, which settled at $2.71. In addition, Allogene Therapeutics Inc saw -6.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who proposed sale 36,404 shares at the price of $2.84 back on Oct 21 ’24. After this action, Parker Geoffrey M. now owns shares of Allogene Therapeutics Inc, valued at $103,501 using the latest closing price.
Douglas Earl Martin, the Officer of Allogene Therapeutics Inc, proposed sale 28,310 shares at $2.79 during a trade that took place back on Aug 21 ’24, which means that Douglas Earl Martin is holding shares at $78,844 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -3148.66 for the present operating margin
- -759.84 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -3237.8. The total capital return value is set at -0.44. Equity return is now at value -48.94, with -39.28 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -739.85.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 6405.57. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.25.
Conclusion
In a nutshell, Allogene Therapeutics Inc (ALLO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
